Clinical trial DEPLETHINK - LymphoDEPLEtion and THerapeutic Immunotherapy with NKR-2
An open-label, Phase I study to assess the safety of NKR-2 treatment administration after a non-myeloablative preconditioning chemotherapy in relapse/refractory acute myeloid leukemia or myelodysplastic syndrome patients
| Cancers | |
|---|---|
| Organ | Multiple |
| Trial status | Trial closed |
| Investigator | |
| Trial type |
Interventional with experimental drug
|
| Phase | Trial phase 1 |
| Academic trial | Non |
| Sponsor | Celyad |
| EudraCT Identifier | 2018-000205-22 |
| ClinicalTrials.gov | https://clinicaltrials.gov/ct2/show/NCT03466320 |
| Inclusion criteria | any line |
| Last update |